1. Home
  2. DFP vs ALT Comparison

DFP vs ALT Comparison

Compare DFP & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

DFP

Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

HOLD

Current Price

$20.86

Market Cap

427.4M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.28

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFP
ALT
Founded
2013
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
427.4M
421.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
DFP
ALT
Price
$20.86
$3.28
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
67.9K
2.6M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
6.73%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$19.09
$2.87
52 Week High
$22.11
$7.73

Technical Indicators

Market Signals
Indicator
DFP
ALT
Relative Strength Index (RSI) 55.54 42.47
Support Level $20.39 $2.87
Resistance Level $20.98 $4.25
Average True Range (ATR) 0.25 0.16
MACD 0.12 0.05
Stochastic Oscillator 96.28 60.45

Price Performance

Historical Comparison
DFP
ALT

About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.

Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: